CytomX Therapeutics

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$18,658
$50,917
$38,093
$33,432
Gross Profit
18,658
50,917
38,093
33,432
EBITDA
-939
23,006
18,092
4,540
EBIT
-1,286
22,621
17,679
4,111
Net Income
-154
23,525
18,876
5,736
Net Change In Cash
18,658
50,917
38,093
33,432
Free Cash Flow
-15,780
-21,162
-19,988
-20,748
Cash
49,041
47,604
38,052
40,576
Basic Shares
129,075
87,150
80,099
85,204

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$138,103
$101,214
$53,163
$69,573
Gross Profit
138,103
101,214
53,163
69,573
EBITDA
26,763
-4,309
-98,892
-81,075
EBIT
24,995
-6,484
-101,335
-83,781
Net Income
31,869
-569
-97,299
-80,648
Net Change In Cash
138,103
101,214
53,163
69,573
Cost of Revenue
13,671
13,671
Free Cash Flow
-86,541
-56,875
-112,528
-120,640
Cash
38,052
17,171
193,650
205,530
Basic Shares
84,745
73,808
65,739
64,146

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.001
2025-03-31
$0.27
2024-12-31
$0.23